Wedbush Lowers Pacira Pharmaceuticals (PCRX) Price Target to $80.00

Pacira Pharmaceuticals (NASDAQ:PCRX) had its target price decreased by equities research analysts at Wedbush from $72.00 to $80.00 in a report released on Monday. The firm currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 139.16% from the company’s current price. Wedbush also issued estimates for Pacira Pharmaceuticals’ Q1 2018 earnings at ($0.14) EPS, Q2 2018 earnings at ($0.12) EPS, Q3 2018 earnings at ($0.22) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($0.25) EPS, FY2021 earnings at $1.36 EPS and FY2022 earnings at $1.89 EPS.

PCRX has been the topic of several other reports. JPMorgan Chase restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th. Canaccord Genuity upped their price objective on shares of Pacira Pharmaceuticals from $32.00 to $34.00 and gave the stock a “hold” rating in a report on Monday. BidaskClub lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 17th. Finally, Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $44.35.

Shares of PCRX stock traded down $1.10 during trading hours on Monday, hitting $33.45. The company had a trading volume of 1,628,686 shares, compared to its average volume of 1,212,933. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96. Pacira Pharmaceuticals has a fifty-two week low of $26.95 and a fifty-two week high of $52.47.



Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The firm had revenue of $79.08 million for the quarter, compared to analyst estimates of $79.06 million. During the same period in the prior year, the business posted $0.09 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. research analysts forecast that Pacira Pharmaceuticals will post -0.51 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in PCRX. First Republic Investment Management Inc. purchased a new stake in Pacira Pharmaceuticals during the 4th quarter worth approximately $201,000. Bouchey Financial Group Ltd purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $205,000. Twin Focus Capital Partners LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $206,000. Redmile Group LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $237,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 4th quarter valued at approximately $241,000.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/12/pacira-pharmaceuticals-pcrx-price-target-cut-to-72-00.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply